Adalvo is pleased to announce that the successful Pivotal BE Study for Bosutinib Film Coated Tablets has been completed, and we are currently preparing for our DCP submission, scheduled for November 2023.
This product is used for the treatment of chronic myelogenous leukemia. In 2022, this product was sold at $603M globally, with a 3Y CAGR of 10% (according to IQVIA).
The successful development of this product further highlights Adalvo's ability to offer difficult-to-make, high-value products to their partners.
As a company committed to their oncology portfolio, Adalvo offers an array of dossiers and aims to assist our partners in overcoming any challenges that may arise with these mature products.
Our varied oncology products include, but are not limited to:
- Afatinib Film-Coated Tablets
- Azacitidine Tablets
- Cabozantinib Film-Coated Tablets
- Ibrutinib Film Coated Tablets
- Lenvatinib Hard Capsules
- Midostaurin Capsules
- Nintedanib Soft Gel Capsules
- Palbociclib Film-Coated Tablets
- Pomalidomide Hard Capsules
- Trametinib Tablets
- Venetoclax Tablets
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
arni.baldursson@adalvo.com - Head of Global BD&L
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
marta.puig@adalvo.com - South Europe
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
marc.nolasco@adalvo.com - Central and Western Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!